MERSANA THERAPEUTICS INC (MRSN)
US59045L1061 - Common Stock
Overall MRSN gets a fundamental rating of 2 out of 10. We evaluated MRSN against 587 industry peers in the Biotechnology industry. MRSN has a bad profitability rating. Also its financial health evaluation is rather negative. MRSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MRSN has reported negative net income.
In the past year MRSN has reported a negative cash flow from operations.
MRSN had negative earnings in each of the past 5 years.
In the past 5 years MRSN always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -67.96%, MRSN is not doing good in the industry: 63.93% of the companies in the same industry are doing better.
The Return On Equity of MRSN (-481.76%) is worse than 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.96% | ||
| ROE | -481.76% | ||
| ROIC | N/A |
ROA(3y)-73.18%
ROA(5y)-55.6%
ROE(3y)-275.55%
ROE(5y)-180.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MRSN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRSN has been increased compared to 1 year ago.
Compared to 5 years ago, MRSN has more shares outstanding
The debt/assets ratio for MRSN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -6.09, we must say that MRSN is in the distress zone and has some risk of bankruptcy.
MRSN's Altman-Z score of -6.09 is on the low side compared to the rest of the industry. MRSN is outperformed by 66.15% of its industry peers.
A Debt/Equity ratio of 0.72 indicates that MRSN is somewhat dependend on debt financing.
MRSN's Debt to Equity ratio of 0.72 is on the low side compared to the rest of the industry. MRSN is outperformed by 75.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.09 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
MRSN has a Current Ratio of 3.51. This indicates that MRSN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.51, MRSN is doing worse than 61.71% of the companies in the same industry.
A Quick Ratio of 3.51 indicates that MRSN has no problem at all paying its short term obligations.
The Quick ratio of MRSN (3.51) is worse than 60.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.00% over the past year.
The Revenue has grown by 18.42% in the past year. This is quite good.
Measured over the past years, MRSN shows a very strong growth in Revenue. The Revenue has been growing by 28.33% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q69.23%
Revenue 1Y (TTM)18.42%
Revenue growth 3Y254.11%
Revenue growth 5Y28.33%
Revenue growth Q2Q18.53%
3.2 Future
The Earnings Per Share is expected to grow by 2.75% on average over the next years.
Based on estimates for the next years, MRSN will show a very strong growth in Revenue. The Revenue will grow by 37.56% on average per year.
EPS Next Y52.32%
EPS Next 2Y21.69%
EPS Next 3Y14.26%
EPS Next 5Y2.75%
Revenue Next Year-7.89%
Revenue Next 2Y-15.26%
Revenue Next 3Y-22.25%
Revenue Next 5Y37.56%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRSN. In the last year negative earnings were reported.
Also next year MRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRSN's earnings are expected to grow with 14.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.69%
EPS Next 3Y14.26%
5. Dividend
5.1 Amount
No dividends for MRSN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MERSANA THERAPEUTICS INC
NASDAQ:MRSN (5/16/2024, 7:05:33 PM)
After market: 2.58 0 (0%)2.58
+0.01 (+0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap315.69M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.96% | ||
| ROE | -481.76% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.72 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.51 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)18.42%
Revenue growth 3Y254.11%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y